Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531145 | 0.99 | HTR6 (0.48) | HTR6HRH3HTR2AHTR7TDP1 | |
| SCHEMBL3535732 | 0.89 | HTR6 (0.48) | HTR6HRH3HTR2AHTR7TDP1 | |
| SCHEMBL3532243 | 0.88 | HTR6 (0.49) | HTR6HRH3HTR2AHTR7TDP1 | |
| SCHEMBL3532997 | 0.88 | HTR6 (0.53) | HTR6HRH3HTR2AHTR7TDP1 | |
| SCHEMBL3536811 | 0.88 | HTR6 (0.43) | HTR6HRH3HTR2AHTR7 | |
| SCHEMBL3534797 | 0.87 | HTR6 (0.47) | HTR6HRH3HTR2AHTR7TDP1 | |
| SCHEMBL3530152 | 0.87 | HTR6 (0.54) | HTR6HRH3HTR2AHTR7TDP1 | |
| SCHEMBL3534246 | 0.86 | HTR6 (0.42) | HTR6HRH3HTR2AHTR7TDP1 | |
| SCHEMBL3532720 | 0.86 | TDP1 (0.47) | HTR6HRH3HTR2AHTR7TDP1 | |
| SCHEMBL3075998 | 0.82 | HTR1B (0.50) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | claimed |
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | HTR6, TPH1, HTR1A | HTR6 1/4885HRH3 534/4885HTR2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.